Scholarlink

<p>Carnitine is essential for mitochondrial fatty acid β-oxidation and redox homeostasis, and mounting evidence shows that carnitine metabolism is profoundly perturbed in diabetic kidney disease (DKD). These abnormalities were previously regarded as secondary epiphenomena of metabolic dysfunction, but accumulating evidence now indicates that they arise from hyperglycaemia-driven OCTN2 impairment, insulin resistance, and oxidative stress, together forming a distinct carnitine-related metabolic signature. Plasma acylcarnitine profiles generally provide more robust and reproducible indicators of systemic metabolic disturbance, and selected signatures may outperform the urinary albumin-to-creatinine ratio (UACR) in the early detection of DKD. By contrast, urinary carnitine changes reflect early defects in proximal tubular reabsorption, supporting kidney-specific phenotyping. Accordingly, integrated plasma and urinary profiling may enhance early detection, facilitate risk stratification, and support treatment monitoring. However, interpretation of these signatures may be confounded by kidney function and medication use, and clinical translation will require rigorous external validation, particularly in prospective cohorts and trials specifically designed for DKD.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Carnitine dysregulation in diabetic kidney disease: from pathogenic mechanism to precision biomarker

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月29日

查看全文
  • Yuanhua Dai,
  • Shiru Duan,
  • Yuxi Li,
  • Jin Rong,
  • Hanfei Li,
  • Weiping Su,
  • Xiaoya Wu,
  • Xiaoyu Peng,
  • Huiming Qi,
  • Shunmei Liu,
  • Tingting Zhao

摘要

Carnitine is essential for mitochondrial fatty acid β-oxidation and redox homeostasis, and mounting evidence shows that carnitine metabolism is profoundly perturbed in diabetic kidney disease (DKD). These abnormalities were previously regarded as secondary epiphenomena of metabolic dysfunction, but accumulating evidence now indicates that they arise from hyperglycaemia-driven OCTN2 impairment, insulin resistance, and oxidative stress, together forming a distinct carnitine-related metabolic signature. Plasma acylcarnitine profiles generally provide more robust and reproducible indicators of systemic metabolic disturbance, and selected signatures may outperform the urinary albumin-to-creatinine ratio (UACR) in the early detection of DKD. By contrast, urinary carnitine changes reflect early defects in proximal tubular reabsorption, supporting kidney-specific phenotyping. Accordingly, integrated plasma and urinary profiling may enhance early detection, facilitate risk stratification, and support treatment monitoring. However, interpretation of these signatures may be confounded by kidney function and medication use, and clinical translation will require rigorous external validation, particularly in prospective cohorts and trials specifically designed for DKD.

Graphical Abstract